A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MF / mometasone furoate

[Related PubMed/MEDLINE]
Total Number of Papers: 149
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MF  (>> Co-occurring Abbreviation)
Long Form:   mometasone furoate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Comparison of therapeutic effects of inhaled corticosteroids on three subtypes of cough variant asthma as classified by the impulse oscillometry system. BUD, CVA, FP, ICSs, IOS, LCQ
2019 Mometasone furoate intranasal spray is effective in reducing symptoms and adenoid size in children and adolescents with adenoid hypertrophy. AH
2018 A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. CRSwNP, INCSs, NPs
2018 A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. ARD, PMRT, RT
2018 Effect of mometasone furoate nasal spray on the DNA of nasal mucosal cells AR, ICs, SP
2018 Effects of mometasone furoate-impregnated biodegradable nasal dressing on endoscopic appearance in healing process following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study. BNDs, CRS, CRSwNP, ESS, POSE
2018 Local delivery of mometasone furoate from an eluting endotracheal tube. ETT
2018 Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. ALL
2018 Mometasone furoate sinus implant - a new targeted approach to treating recurrent nasal polyp disease. CRS, CRSwNP, ESS
10  2018 Validated Stability-Indicating Methods for Determination of Mometasone Furoate in Presence of its Alkaline Degradation Product. ---
12  2017 Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial. AH, AR, OXY
13  2017 Comparison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis. AR, TDI
14  2017 Effect of a combination of mometasone furoate, levofloxacin, and retinyl palmitate with an in situ gel-forming nasal delivery system on nasal mucosa damage repair in an experimental rabbit model. ---
15  2017 Evaluation of graphical and statistical representation of analytical signals of spectrophotometric methods. GEN, MIC, OPA
16  2017 Expression of intelectin-1 in bronchial epithelial cells of asthma is correlated with T-helper 2 (Type-2) related parameters and its function. BAL, BECs, D-CON, ITLN-1, qPCR, rh, SN-Asthma, ST-Asthma
17  2017 Mometasone furoate (MF) improves lung function in pediatric asthma: A double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler. AEs, DPI, LS, MDI
18  2017 Mometasone Furoate Suppresses PMA-Induced MUC-5AC and MUC-2 Production in Human Airway Epithelial Cells. BUD, PMA, TNF-alpha
19  2017 Strontium chloride hexahydrate as a candidate molecule for long-term treatment of allergic rhinitis. AR, HD, SC
20  2016 Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model. CFD, MP, NV
21  2016 Effects of benzalkonium chloride on histamine H1 receptor mRNA expression in nasal epithelial cells. BKC, H1R, OMZ, RM
22  2016 Is the Wnt/beta-catenin pathway involved in the anti-inflammatory activity of glucocorticoids in spinal cord injury? GCs, MPSS, SCI
23  2016 Longitudinal in vivo tracking of adverse effects following topical steroid treatment. FLIM, FP, SHG, TPEF
24  2016 Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers. BRZ, CI, PK, TH
25  2016 Mometasone furoate nasal spray: a systematic review. ARS, CRS
26  2016 Sustained Inner Ear Steroid Delivery via Bioabsorbable Stent: A Tolerability and Feasibility Study on Guinea Pigs. ---
27  2015 Deposition of intranasal glucocorticoids--preliminary study. FF, FP
28  2015 Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. ICS, LABA
29  2015 Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery. BMP, NGI, SX
30  2015 In-office use of a steroid-eluting implant for maintenance of frontal ostial patency after revision sinus surgery. CRS, ESS
31  2015 Intranasal corticosteroids for mild childhood obstructive sleep apnea--a randomized, placebo-controlled study. OAHI, ODI, OSA
32  2015 Letter to the Editor: Incorrect conclusions regarding deposition of conventional mometasone furoate (MF) nasal spray. ---
33  2015 Mometasone furoate-loaded cold processed oil-in-water emulsions: in vitro and in vivo studies. SC
34  2015 Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. CI, OD, PK
35  2015 Regional deposition of mometasone furoate nasal spray suspension in humans. MFS
36  2015 The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. FXR
37  2015 The influence of mometasone furoate ear solution on intradermal test immediate reactions in dogs with atopic dermatitis. GWS, IDT
38  2015 Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids. DEX, MPSS, SCI
39  2014 An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects. CI, MF-DPI
40  2014 Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. SLNs
41  2014 Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device. FDC, GMRs, MDI
42  2014 Fluticasone furoate is more effective than mometasone furoate in restoring tobacco smoke inhibited SOCS-3 expression in airway epithelial cells. COPD, FF, SOCS-3, TS
43  2014 Microdialysis as a tool to determine the skin concentration of mometason furoate in rats. RR
44  2014 Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. DLQI, HAD, RTOG
45  2014 Mometasone furoate hydrogel for scalp use: in vitro and in vivo evaluation. ---
46  2014 Nanoencapsulation in lipid-core nanocapsules controls mometasone furoate skin permeability rate and its penetration to the deeper skin layers. LNC
47  2014 Regional deposition of mometasone furoate nasal spray suspension in humans. MFS
48  2014 Structures and mechanism for the design of highly potent glucocorticoids. GR, LBD
49  2014 Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo. FF, IFN, IL, SEB, Th, TNF
50  2013 A review of mometasone furoate / formoterol in the treatment of asthma. AHR, ICS, LABA
51  2013 Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. CI, FF, FP, QOL, SAR, SFD
52  2013 Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysis. AEs, ICSs
53  2013 Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. CI, COPD, DPI, GMR
54  2013 Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Phenoxyethanol, Methylparaben, Propylparaben, Mometasone Furoate, and Tazarotene in Topical Pharmaceutical Dosage Formulation. MP, PE, PP, TA
55  2013 Effects of corticosteroids on hyposmia in persistent allergic rhinitis. FF, OD, OI, OT, PER, VAS
56  2013 Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma. BMD, FP, ICS, LS, ML
57  2013 Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice. cGR, GCs, mGR, PLA2, PLC
58  2013 Optimized methods for in vitro and in vivo anti-inflammatory assays and its applications in herbal and synthetic drug analysis. GCs, IFN-gamma, IL-1, IL-4, NO, PPS, ROS, SOD, TNF-alpha
59  2013 Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler. DPI, MMAD
60  2013 Post-steroid management of chronic vulvar itching with a topical formula containing natural anti-itching and anti-inflammatory actives. ---
61  2013 Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 mug/50 mug versus mometasone furoate inhalation powder. ED, HO, ICSs, PO, SCSs
62  2013 The role of mometasone furoate nasal spray in the treatment of adenoidal hypertrophy in the adolescents: a prospective, randomized, cross-over study. ---
63  2012 Effect of nasal mometasone furoate on the nasal and nasopharyngeal flora. ---
64  2012 Mometasone furoate gel: a novel in-office treatment of recalcitrant postoperative chronic rhinosinusitis. ESS
65  2012 Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. ---
66  2011 Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats. BAL, FVC, ICS/LABA, IL, TNF-alpha
67  2011 Recruitment factors which affect the outcome of a seasonal allergic rhinitis trial. INSs, NPIF, RQLQ, SAR
68  2011 Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. CIC, FF, INSs
69  2011 Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. AR, BDP, BUD, FF, FP, INS, TIX, TRIAM
70  2011 Treatment with inhaled mometasone furoate reduces short-acting beta(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. FP
71  2010 Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. ---
72  2010 Olfactory cleft inflammation is present in seasonal allergic rhinitis and is reduced with intranasal steroids. AR, NPIF, SAR
73  2010 Preoperative treatment with topical corticoids and bleeding during primary endoscopic sinus surgery. CI, CRS, ESS
74  2010 The impact of adherence and disease control on resource use and charges in patients with mild asthma managed on inhaled corticosteroid agents. HCHA, ICSs, LCLA
75  2010 To treat snoring with nasal steroids - effects on more than one level? ---
76  2010 Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. ICS
77  2009 A simple RP-HPLC method for the simultaneous quantitation of chlorocresol, mometasone furoate, and fusidic acid in creams. CC, FA
78  2009 Different approaches for improving skin accumulation of topical corticosteroids. CP
79  2009 Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice. BDP
80  2009 Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. BUD, FF, FP, TCA
81  2009 Frequency of dosing and comparative doses of mometasone furoate: a meta-analysis. ---
82  2009 Moderate leukocyte infiltration in the lower turbinate mucosa after a two-week intranasal administration of mometasone furoate, azelastine or salmon calcitonin. AZ, SC
83  2009 Mometasone furoate vs fluticasone propionate with salmeterol: multivariate analysis of resource use and asthma-related charges. FPS, ICS, NAEPP
84  2009 Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. ICS
85  2009 [Intranasal steroid therapy in inflammatory nasal-sinus pathology in pediatric age]. ---
86  2008 Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. DPI, FP, ICSs, PEFR
87  2008 Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis. AR, DLR, MSK
88  2008 Intracellular delivery of nanoparticles of an antiasthmatic drug. ---
89  2008 Mometasone furoate in the management of asthma: a review. ICS
90  2008 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function. ---
91  2007 Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite. BUD, CIC, FP, GCS
92  2007 Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. FF, FP, RRA, RRA
93  2007 Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. MDI, OCS
94  2007 Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma. ICS, ICSs, MF-DPI, OCSs
95  2007 Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. FP
96  2006 Metabolism of mometasone furoate and biological activity of the metabolites. RBA
97  2006 Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice. ---
98  2005 A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma. LLOQ
99  2005 Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. FP, INCSs
100  2005 Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. NBS, PAR, PNIF, XYLO